Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective
Our findings identified trends in olaparib and pancreatic cancer, with China and the USA leading and with global cooperation tightening. O'Reilly EM's team and Memorial Sloan-Kettering had the highest output. The <i>Journal of Clinical Oncology</i> was the most cited journal. More PARP inhibitors are emerging, and combination therapy is suggested for future therapeutic trends.
Authors
- Wenbin Jiang (ORCID: https://orcid.org/0009-0004-8559-2734)
- Ying Chai (ORCID: https://orcid.org/0000-0002-4179-050X)
- Kexin Jiang (ORCID: https://orcid.org/0009-0005-6675-0159)
- Wenchao Chen (ORCID: https://orcid.org/0000-0001-7613-1734)
- Yu Pan (ORCID: https://orcid.org/0009-0006-7066-3100)
- Feng Xu (ORCID: https://orcid.org/0000-0002-7827-2319)
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.4251/wjgo.v16.i11.4489
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00